Meeting
2022 ASCO Annual Meeting
HER2 alterations and prognostic implications in all subtypes of breast cancer.
Authors
Kaitlyn O'Keefe
Atrium Health Levine Cancer Institute, Charlotte, NC
Kaitlyn O'Keefe , Andrew Elliott , Chad Livasy , Meghan Steiner , Irene Kang , Dave S. B. Hoon , Wolfgang Michael Korn , Phillip Walker , Milan Radovich , Paula R Pohlmann , Sandra M. Swain , Antoinette R. Tan , Arielle Lutterman Heeke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1041)
DOI
10.1200/JCO.2022.40.16_suppl.1041
Abstract #
1041
Poster Bd #
419
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
First Author: Beatrice Bachmeier
Poster
2011 ASCO Annual Meeting
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
First Author: D. Gajria
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges
Poster
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
First Author: Joshua Z. Drago